Митці та їх залежності: між натхненням та саморуйнуванням

Олівер Шнелл, Хайме Альмандос, Ліза Андерсон, Кетрін Барнард-Келлі, Тадей Баттеліно, Маттіас Блюхер, Лука Бусетто, Дойна Катріну, Томас Данне, Антоніо Серіелло, Ксав’єр Кос, Колін М. Даян, Беатріс Фернандес-Фернандес, Стефано Дель Прато, Паола Фіоретто, Томас Форст, Франческо Джорджіно, Джеймс Р. Гевін, Пер-Генрік Груп, Хіддо Дж. Херспінк, Лутц Хайнеманн,
Ігор А. Харш, Махмуд Ібрагім, Мішель Жадул, Сара Джарвіс, Лінонг Цзі, Нареш Кануміллі, Михайло Косібород, Ульф Ландмессер, Софія Мацейра, Борис Маньковський, Ніколаус Маркс, Шанталь Матьє, Барбара Макгоуен, Тетяна Міленкович, Отмар Мозер, Дірк Мюллер-Віланд, Ніколаос Папанас, Діпеш К. Патель, Андреас Ф.Х. Пфайффер, Даріо Рахеліч, Хелена В. Родбард, Ларс Райден, Ельке Шеффнер, Венді Спірман, Алін Стірбан, Франк Таке, Пінар Топсевер, Люк Ван Гаал, Еберхард Стендл

DOI :

Резюме

10-й Саміт з питань серцево-судинних наслідків (CVOT): Конгрес з питань серцево-судинних, ниркових та метаболічних наслідків відбувся онлайн 5–6 грудня 2024 року. Цього року обговорення досліджень серцево-судинних (СС) та ниркових наслідків було зосереджено на нещодавніх результатах досліджень, що включали емпагліфлозин (EMPACT-MI), семаглутид (STEP-HFpEF-DM та FLOW), тирзепатид (SURMOUNT-OSA та SUMMIT) та фінеренон (FINEARTS-HF). Ці дослідження представляють значний прогрес у зниженні ризику серйозних несприятливих серцево-судинних подій (MACE) та покращенні метаболічних результатів при серцевій недостатності зі збереженою фракцією викиду (СНзбФВ), хронічній хворобі нирок (ХХН) та обструктивному апное сну (ОSА). Конгрес також включав сесії, присвячені новим та встановленим методам лікування СНзбФВ, ХХН та ожиріння; рекомендаціям щодо лікування ХХН та метаболічно-асоційованої стеатотичної хвороби печінки (МАСХП); розвитку кардіо-рено-метаболічного синдрому (КРМС); персоніфікованій медицині та орієнтованого на пацієнта лікування діабету, ожирінню, серцево-судинних захворюваням (ССЗ) та ХХН; раннєму виявленню цукрового діабету (ЦД) 1-го типу та стратегії затримки його розвитку; безперервному моніторингу глюкози (CGM) та автоматизованій доставці інсуліну (AID); кардіальній автономной нейропатії (КАН) та діабетичному серцю та ролі первинної медичної допомоги у ранньому виявленні, профілактиці та лікуванні ХХН. Внесок забруднення навколишнього середовища пластиком у ризик серцево-судинних захворювань, зростаюче розуміння ефективності та безпеки інкретинової терапії в лікуванні ХХН та останні оновлення щодо стратегій харчування для лікування ХХН при терапії на основі інкретинів також були темами, що цікавили широку аудиторію ендокринологів, діабетологів, кардіологів, нефрологів та лікарів первинної медичної допомоги, які активно брали участь в онлайн-дискусіях. 11-й саміт CVOT відбудеться онлайн 20–21 листопада 2025 року (http://www.cvot.org).

Ключові слова: серцево-судинні захворювання, хронічна хвороба нирок, безперервний моніторинг глюкози (CGM), діабет, фінеренон, ГПП-1, рекомендації, серцева недостатність, метаболічно-асоційована стеатотична хвороба печінки, ожиріння, інгібітор НЗКТГ2, тирзепатид.

Література

  1. Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes—guidance document. 2008.
  2. (FDA) USFaDA. Type 2 diabetes mellitus: evaluating the safety of new drugs for improving glycemic control guidance for industry (Draft) 2020 [Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/type-2-diabetes-mellitus-evaluating-safety-new-drugs-improving-glycemic-control-guidance-industry.
  3. (NCD-RisC) NRFC. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 2024; 404(10467): 2077–93.
  4. Federation WO. Prevalence of obesity 2024 [Available from: https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity.
  5. Blüher M, Ceriello A, Davies M, Rodbard H, Sattar N, Schnell O, et al. Managing weight and glycaemic targets in people with type 2 diabetes-how far have we come? Endocrinol Diabetes Metab. 2022;5(3): e00330.

 

  1. Gupta S, Bansal S. Does a rise in BMI cause an increased risk of diabetes?: Evidence from India. PLoS ONE. 2020;15(4): e0229716.

 

  1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.

 

  1. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.
  2. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol CJASN. 2017;12(12):2032–45.
  3. American Diabetes Association. Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(1):S1–232.
  4. Kounatidis D, Vallianou NG, Stratigou T, Voukali M, Karampela I, Dalamaga M. The kidney in obesity: current evidence perspectives and controversies. Curr Obes Rep. 2024;13(4):680–702.
  5. Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2018;20(5):853–72.
  6. Vidal-Cevallos P, Sorroza-Martínez AP, Chávez-Tapia NC, Uribe M, Montalvo-Javé EE, Nuño-Lámbarri N. The relationship between pathogenesis and possible treatments for the MASLD-cirrhosis spectrum. Int J Mol Sci. 2024;25(8):4397.

 

  1. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841–58.

 

  1. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687–98.
  2. Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus-an overview. Int J Mol Sci. 2024;25(3):1882.
  3. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–23.
  4. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.
  5. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

 

  1. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.
  2. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79.
  3. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–66.
  4. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

 

  1. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

 

  1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
  2. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.
  3. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39.
  4. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.
  5. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
  6. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
  7. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.
  8. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.
  9. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907.
  10. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.
  11. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63.

 

  1. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
  2. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.
  3. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28.
  4. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.
  5. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.
  6. James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D, Hofmann R. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3(2):2300286.
  7. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84.
  8. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

 

  1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

 

  1. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27.
  2. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.
  3. Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, et al. Finerenone and heart failure outcomes by kidney function/albuminuria in chronic kidney disease and diabetes. JACC Heart Fail. 2022;10(11):860–70.
  4. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
  5. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84.
  6. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–13.
  7. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–25.
  8. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55.
  9. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.
  10. Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. 2021;398(10300):583–98.
  11. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–24.
  12. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–45.
  13. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.

 

  1. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JP, Perreault L, Zhang S, Battula R, Bunck MC. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958–71.
  2. Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% [press release].
  3. Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390(16):1455–66.
  4. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394–407.
  5. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427–37.
  6. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475–85.
  7. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–21.
  8. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193–205.
  9. Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2016;15:33.
  10. Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 2nd cardiovascular outcome trial (CVOT) summit of the diabetes and cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2017;16(1):35.
  11. Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, et al. Report from the 3rd cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2018;17(1):30.
  12. Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, et al. Report from the 4th cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2019;18(1):30.
  13. Schnell O, Standl E, Cos X, Heerspink HJ, Itzhak B, Lalic N, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47.
  14. Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75.
  15. Schnell O, Battelino T, Bergenstal R, Blüher M, Böhm M, Brosius F, et al. Report from the CVOT summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol. 2022;21(1):50.

 

  1. Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, et al. CVOT summit 2022 report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2023;22(1):59.
  2. Schnell O, Barnard-Kelly K, Battelino T, Ceriello A, Larsson HE, Fernández-Fernández B, et al. CVOT summit report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2024;23(1):104.
  3. Hilbe JM. Negative binomial regression. 2nd ed. Cambridge: Cambridge University Press; 2011.
  4. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2011;33(2):176–82.
  5. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J R Stat Soc Ser B Stat Methodol. 2002;62(4):711–30.
  6. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Med. 2016;21(4):125–7.
  7. Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023;29(10):2438–57.
  8. Gavin JR, Rodbard HW, Battelino T, Brosius F, Ceriello A, Cosentino F, et al. Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases—recommendations from the taskforce of the guideline workshop. Diabetes Res Clin Pract. 2024;211: 111666.
  9. Barnard-Kelly K, Marrero D, de Wit M, Pouwer F, Khunti K, Hermans N, et al. Towards the standardisation of adult person-reported outcome domains in diabetes research: a consensus statement development panel. Diabetic Med J Br Diabetic Assoc. 2024;41(8): e15332.

 

  1. KDIGOKCW. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024; 105(4s): S117–S314.
  2. (EASO). EAftSotLEEAftSoDEEAftSoO. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81(3): 492–542.
  3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39.
  4. Chertow GM, Correa-Rotter R, Eckardt KU, Kanda E, Karasik A, Li G, et al. Projecting the clinical burden of chronic kidney disease at the patient level (inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72: 102614.
  5. Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clin Kidney J. 2024;17(Suppl 2):19–35.
  6. Parksook WW, Williams GH. Aldosterone and cardiovascular diseases. Cardiovasc Res. 2022;119(1):28–44.
  7. Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403(10424):379–90.
  8. Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O’Meara E, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(11): e005288.
  9. Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 trial of Baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395–405.
  10. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association. Circulation. 2023;148(20):1606–35.
  11. (WHO) WHO. Cardiovascular diseases (CVDs) 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29.
  12. Rajagopalan S, Landrigan PJ. Pollution and the heart. N Engl J Med. 2021;385(20):1881–92.
  13. Zhu X, Wang C, Duan X, Liang B, Genbo XuE, Huang Z. Micro- and nanoplastics: a new cardiovascular risk factor? Environ Int. 2023;171: 107662.
  14. Microplastics are everywhere—we need to understand how they affect human health. Nat Med 2024; 30(4): 913.
  15. Marfella R, Prattichizzo F, Sardu C, Fulgenzi G, Graciotti L, Spadoni T, et al. Microplastics and nanoplastics in atheromas and cardiovascular events. N Engl J Med. 2024;390(10):900–10.
  16. The Lancet Diabetes E. Diabetes education: the key to a brighter tomorrow. Lancet Diabet Endocrinol. 2022; 10(12): 827.
  17. Committee ADAPP. American diabetes association—standards of care 2024. Diabetes Care. 2024; 47: S1–S313.
  18. Network GBoDC. Global burden of disease study 2021. Results. Institute for health metrics and evaluation. 2024 [Available from: https://vizhub.healthdata.org/gbd-results/.
  19. Quinn LM, Wong FS, Narendran P. Environmental determinants of type 1 diabetes: from association to proving causality. Front Immunol. 2021;12: 737964.

 

  1. Tatovic D, Narendran P, Dayan CM. A perspective on treating type 1 diabetes mellitus before insulin is needed. Nat Rev Endocrinol. 2023;19(6):361–70.
  2. Phillip M, Achenbach P, Addala A, Albanese-O’Neill A, Battelino T, Bell KJ, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care. 2024;47(8):1276–98.
  3. Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, et al. Teplizumab and β-cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023;389(23):2151–61.
  4. Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked. Controlled Trial Diabetes Care. 2023;46(5):1005–13.
  5. Seferović PM, Paulus WJ, Rosano G, Polovina M, Petrie MC, Jhund PS, et al. Diabetic myocardial disorder. A clinical consensus statement of the heart failure association of the ESC and the ESC working group on myocardial & pericardial diseases. Eur J Heart Fail. 2024;26(9):1893–903.
  6. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes. 2007;56(10):2457–66.
  7. Regan JA, Mentz RJ, Nguyen M, Green JB, Truby LK, Ilkayeva O, Newgard CB, Buse JB, Sourij H, Sjöström CD, Sattar N. Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 2023;8(17):e168563.
  8. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639–53.

 

  1. Davis TME, Tan E, Davis WA. Prevalence and prognostic significance of cardiac autonomic neuropathy in community-based people with type 2 diabetes: the Fremantle diabetes study phase II. Cardiovasc Diabetol. 2024;23(1):102.
  2. Eleftheriadou A, Spallone V, Tahrani AA, Alam U. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. 2024;67(12):2611–25.
  3. Jancev M, Vissers T, Visseren FLJ, van Bon AC, Serné EH, DeVries JH, et al. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetologia. 2024;67(5):798–810.
  4. Ajjan RA, Battelino T, Cos X, Del Prato S, Philips JC, Meyer L, et al. Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nat Rev Endocrinol. 2024;20(7):426–40.
  5. Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al. Multicenter randomized trial of intermittently scanned continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes and recent-onset acute myocardial infarction: results of the LIBERATES trial. Diabetes Care. 2023;46(2):441–9.
  6. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–8.
  7. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–28.
  8. Moser O, Zaharieva D, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, et al. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European association for the study of diabetes (EASD) and the international society for pediatric and adolescent diabetes (ISPAD). Horm Res Paediatr. 2024;68:1–28.
  9. Moser O, Zaharieva DP, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, et al. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European association for the study of diabetes (EASD) and the international society for pediatric and adolescent diabetes (ISPAD). 2025;68(2):255–80.
  10. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. 2006;444(7121):875–80.
  11. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593–606.

 

  1. Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Østergaard L, Vanni D, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60(11–12):1525–33.

 

  1. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310.
  2. Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311–9.
  3. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. 2014;383(9918):736–47.
  4. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008;5(2):173–8.
  5. de Toro-Martín J, Arsenault BJ, Després JP, Vohl MC. Precision nutrition: a review of personalized nutritional approaches for the prevention and management of metabolic syndrome. Nutrients. 2017;9(8):913.
  6. Trouwborst I, Gijbels A, Jardon KM, Siebelink E, Hul GB, Wanders L, et al. Cardiometabolic health improvements upon dietary intervention are driven by tissue-specific insulin resistance phenotype: a precision nutrition trial. Cell Metab. 2023;35(1):71-83.e5.
  7. Quast DR, Nauck MA, Schenker N, Menge BA, Kapitza C, Meier JJ. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes Obes Metab. 2021;23(10):2344–53.
  8. Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care. 2024;47(10):1718–30.
  9. Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–30.
  10. Almandoz JP, Wadden TA, Tewksbury C, Apovian CM, Fitch A, Ard JD, et al. Nutritional considerations with antiobesity medications. Obesity. 2024;32(9):1613–31.
PDF (українська)

Опубліковано: 2025

Як цитувати:

Митці та їх залежності: між натхненням та саморуйнуванням (2025). Діабет Ожиріння Метаболічний синдром 4(14), 70-72.